Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,984 DKK | +63.02% | +4.14% | +14.24% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Sales 2024 * | 19.68B 2.82B | Sales 2025 * | 23.49B 3.37B | Capitalization | 130B 18.68B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 732M | Net income 2025 * | 6.76B 969M | EV / Sales 2024 * | 5.23 x |
Net cash position 2024 * | 27.32B 3.92B | Net cash position 2025 * | 34.49B 4.95B | EV / Sales 2025 * | 4.08 x |
P/E ratio 2024 * |
25.5
x | P/E ratio 2025 * |
19.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-0.27% | 105B | |
+4.25% | 97.5B | |
+2.01% | 22.19B | |
-15.61% | 21.33B | |
-41.41% | 16.6B | |
-19.67% | 14.52B | |
+6.71% | 14.09B | |
+22.71% | 10.99B | |
-21.51% | 8.63B |